Study of MP101 for adults with Pseudomonas pneumonia
Part of Infections, Lungs & breathing clinical trials.
This trial tests an experimental treatment called MP101 for adults with pneumonia caused by the bacteria Pseudomonas aeruginosa (PA). It aims to help patients whose infection is not responding to current antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years old or older.
- You must have pneumonia confirmed by a chest X-ray or CT scan.
- You must have a positive test for Pseudomonas aeruginosa from a sputum or lung sample.
- Your PA infection must be sensitive to the study drug but not sensitive to your current antibiotic.
- Your liver, kidney, and blood cell health must be within acceptable limits.
- You cannot have severe sepsis, active tuberculosis, or be immunocompromised.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (OPT101) for people hospitalized with pneumonia and sepsis—where a lung infection causes body-wide inflammation and low oxygen. It aims to help patients who need extra oxygen but are not yet on a breathing machine.
This study tests a specific antibiotic plan for adults with a hard-to-treat Pseudomonas infection that needs IV medicine. It aims to find the best way to treat these serious infections.
This trial tests two different antibiotic treatments for adults with bronchiectasis who have a new or recent infection with Pseudomonas aeruginosa (PA) bacteria in their airways. The goal is to see which regimen works better to clear the infection early.
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This trial is testing how many days of antibiotics are best for adults with pneumonia who are treated by their regular doctor (not in a hospital). The goal is to find the shortest effective treatment to reduce side effects and antibiotic resistance.
Hear when a new Pneumonia, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.